An EML4-ALK rearrangement was found after acquired resistance to EGFR TKI treatment. Crizotinib was administered. The patient's lung lesions continued to progress after 1 month of crizotinib treatment, and pemetrexed-bevacizumab was initiated. After two cycles of chemotherapy, the metastatic cancers shrunk, and the patient maintained stable disease at his last follow-up. The gene discussed is ALK; the disease is metastatic malignant neoplasm.